Key Highlights

• Rani Therapeutics (NASDAQ: RANI) appoints Nicholas Maestas as Chief Financial Officer, effective June 29, 2026.

• Maestas receives a $500,000 annual base salary and is eligible for a bonus targeting 75% of his salary.

• The company grants Maestas options to purchase 2 million shares, with vesting structured over four years.

• Rani Therapeutics reserves 5.5 million shares under a 2026 inducement plan for future equity awards.

Rani Therapeutics (NASDAQ: RANI) has brought in a seasoned finance executive to steer its financial strategy. The biotech firm announced the appointment of Nicholas Maestas as its new Chief Financial Officer, marking a leadership transition in its executive ranks.

Leadership Transition

Rani Therapeutics named Nicholas Maestas as CFO, effective June 29, 2026. He succeeds Svai Sanford, who previously announced plans to step down upon the appointment of a successor. The move reflects the company’s focus on strengthening its financial leadership amid ongoing development efforts in the biotech sector, where financial discipline is critical for navigating clinical trials and commercialization.

Maestas’ Professional Background

Maestas joins Rani Therapeutics with nearly a decade of experience in biopharma finance. His most recent role was as CFO and Head of Corporate Strategy at Tempest Therapeutics, where he served from January 2025 to June 2026. Prior to that, he held senior finance positions at Alector and Immune Design, the latter of which was acquired by Merck & Co in 2019.

His background includes expertise in capital markets, strategic planning, and financial operations, skills that are particularly valuable for a company in Rani’s stage of growth.

Compensation Package

The new CFO will receive a $500,000 annual base salary, with an annual bonus target set at 75% of his salary. His compensation package also includes a non-qualified stock option grant for 2 million shares, a common practice in biotech to align executive incentives with long-term shareholder value. Such equity awards are often structured to reward performance and retention in an industry where leadership stability can significantly impact investor confidence.

Stock Option Vesting Terms

Maestas’ stock options will vest over a four-year period. A quarter of the shares will become exercisable after the first year of his tenure, with the remainder vesting in subsequent installments. This approach is designed to encourage long-term commitment while providing incremental rewards for continued service.

Vesting schedules like this are standard in executive compensation packages, particularly in high-growth sectors where retaining key talent is essential.

Inducement Plan Approval

Rani Therapeutics’ board approved a 2026 inducement plan on June 28, reserving 5.5 million shares for future equity grants. The plan is intended to support the recruitment and retention of new employees, a priority for companies expanding their teams in competitive talent markets. The board’s decision complies with Nasdaq Rule 5635, which allows such awards to be made without shareholder approval under specific conditions, ensuring flexibility in attracting top-tier candidates.

Severance and Indemnification

Maestas will be covered under the company’s Severance Plan, as referenced in the offer letter.1 and detailed in Exhibits 10.8 and 10.9. Additionally, he will enter into an indemnification agreement, which provides legal protections consistent with those offered to other executives in publicly traded companies. These arrangements are typical in corporate governance, offering executives safeguards while ensuring alignment with company policies.

Strategic Implications

The appointment of a finance veteran with biotech experience signals Rani Therapeutics’ commitment to operational discipline. Maestas’ background in corporate strategy and financial management could play a key role in shaping the company’s approach to capital allocation, funding strategies, and investor relations. As Rani advances its pipeline, stakeholders will likely monitor how his leadership influences financial decision-making and long-term growth initiatives in the competitive biotech landscape.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.